{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:03:02Z","timestamp":1789448582730,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470211"],"award-info":[{"award-number":["82470211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2022YZ034016"],"award-info":[{"award-number":["2022YZ034016"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2021ZD01005"],"award-info":[{"award-number":["2021ZD01005"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) harboring favorable-risk genetic features at initial diagnosis (FR-AML) commonly achieves remission after chemotherapy, but the optimal post-remission strategy remains controversial. This study compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy and explored prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 190 patients with FR-AML treated at Fujian Medical University Union Hospital between 2012 and 2022. Patients were stratified into the chemotherapy (n = 118) and allo-HSCT (n = 72) groups according to their post-induction treatment. Survival outcomes, including overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM), were assessed using Kaplan\u2013Meier and competing-risk analyses. Multivariate Cox regression identified independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 3 years, the allo-HSCT group had higher OS (86.0% vs. 61.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001) and LFS (59.2% vs. 49.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.039) than the chemotherapy group, with lower CIR (3.8% vs. 33.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001). Stratified analyses showed that allo-HSCT was associated with improved 3-year OS compared with chemotherapy alone in CR1-AML and R\/R AML patients. In CR1-AML, the 3-year OS was 92.8% versus 73.6% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0099), whereas in R\/R AML, it was 73.5% versus 26.6% (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.00015). By age, outcomes were comparable among patients aged &amp;lt;20 years, whereas allo-HSCT was associated with better survival in those aged 20\u201360 years. Among 66 transplanted patients with measurable residual disease (MRD) data, 3-year OS did not differ significantly between MRD-positive and MRD-negative groups (86.0% vs. 85.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.35).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Allo-HSCT was associated with improved survival and reduced relapse in FR-AML. This benefit extended beyond patients transplanted in CR1 to those who later develop R\/R disease, in whom salvage allo-HSCT confers a marked survival advantage over chemotherapy. Deferred transplantation may remain feasible for selected patients when a suitable donor is available. Prospective studies are warranted to validate these findings and optimize post-remission treatment strategies in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1825310","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:27:59Z","timestamp":1789446479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic stem cell transplantation is associated with improved survival compared with chemotherapy in patients with acute myeloid leukemia harboring favorable-risk genetic features at initial diagnosis: a single-center retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Rujiao","family":"Dong","sequence":"first","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wu","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainong","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Translational Medicine Center on Hematology, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7605","article-title":"Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: A randomized clinical trial","volume":"9","author":"Bornh\u00e4user","year":"2023","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"B7","article-title":"Acute myeloid leukemia-genetic alterations and their clinical prognosis","volume":"11","author":"Lagunas-Rangel","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia--major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280765","article-title":"Improved outcomes with \u20187+3\u2019 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data","volume":"108","author":"Othus","year":"2023","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable ('minimal\u2019) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25484","article-title":"Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia","volume":"94","author":"Medeiros","year":"2019","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3324\/haematol.2014.114611","article-title":"Post-remission therapy for acute myeloid leukemia","volume":"99","author":"Schlenk","year":"2014","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144253","article-title":"Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia","volume":"102","author":"Oran","year":"2017","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Cancer Network : JNCCN"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1511057","article-title":"Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12935-022-02750-4","article-title":"Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission","volume":"22","author":"Chen","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503847","article-title":"The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA","volume":"122","author":"Schlenk","year":"2013","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2540-7","article-title":"Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant","volume":"95","author":"Ahn","year":"2016","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27618","article-title":"Reassessing the role of high dose cytarabine and mitoxantrone in relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Canaani","year":"2020","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090755","article-title":"Allogeneic stem cell transplantation in refractory acute myeloid leukaemia","volume":"13","author":"Bono","year":"2024","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0809","article-title":"Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis","volume":"28","author":"Nagler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028730","article-title":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial","volume":"146","author":"Stelljes","year":"2025","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02868","article-title":"What influences the decision to proceed to transplant for patients with AML in first remission","volume":"41","author":"DeWolf","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41408-021-00591-4","article-title":"Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes","volume":"11","author":"Yu","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:28:00Z","timestamp":1789446480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1825310"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825310","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1825310"}}